ALPS Medical Breakthroughs ETF(SBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SBIO ALPS Medical Breakthroughs ETF

交易中 09-18 14:01:48 EDT

61.99

-1.74

-2.74%

最高63.39	最低61.96	成交量1.35万
今开63.39	昨收63.73	日振幅2.24%
总市值2.28亿	流通市值2.28亿	总股本367.50万
成交额84.20万	换手率0.37%	流通股本367.50万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SBIO","market":"US","secType":"STK","nameCN":"ALPS Medical Breakthroughs ETF","latestPrice":61.985,"timestamp":1789754309086,"preClose":63.7282,"halted":0,"volume":13510,"delay":0,"changeRate":-0.02735366760711901,"floatShares":3675000,"shares":3675000,"eps":0,"marketStatus":"交易中","change":-1.7432,"latestTime":"09-18 14:01:48 EDT","open":63.385,"high":63.385,"low":61.96,"amount":842008.75052,"amplitude":0.022361,"askPrice":62.23,"askSize":300,"bidPrice":62.02,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1789761600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":63.7282,"sharesOutstanding":2675000,"nav":62.4,"aum":229323064.49,"bidAskSpread":0.002205,"postHourTrading":{"tag":"盘后","latestPrice":63.5804,"preClose":63.7282,"latestTime":"19:30 EDT","volume":12,"amount":762.8602,"timestamp":1789687804866,"change":-0.1478,"changeRate":-0.002319,"amplitude":0},"volumeRatio":0.410786,"impliedVol":0.2644,"impliedVolPercentile":0.8446},"requestUrl":"/m/hq/s/SBIO","defaultTab":"news","newsList":[{"id":"2668946461","title":"Xenon制药美股盘前跌超28%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668946461","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668946461?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:09","pubTimestamp":1789718975,"startTime":"0","endTime":"0","summary":"【Xenon制药美股盘前跌超28%】Xenon制药美股盘前跌超28%，因公司暂停了抑郁症药物试验的新患者招募。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609183878613718.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609183878613718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["XENE","SBIO","IBRN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106034976","title":"Xenon制药盘前股价暴跌27.5%，因暂停抑郁症药物试验新患者招募","url":"https://stock-news.laohu8.com/highlight/detail?id=1106034976","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106034976?lang=zh_cn&edition=full","pubTime":"2026-09-18 16:06","pubTimestamp":1789718769,"startTime":"0","endTime":"0","summary":"Xenon制药（Xenon Pharmaceuticals）盘前交易中股价大幅下挫，跌幅高达27.5%。这一剧烈波动源于该公司宣布，已决定暂停其抑郁症药物试验的新患者招募工作。市场对此消息反应迅速且激烈，投资者信心受到明显冲击。此举意味着，这家生物制药公司在推进其核心候选药物临床研发进程中，遭遇了意料之外的阻碍。尽管公司方面尚未透露暂停的具体原因，但资本市场已用脚投票，显示出对这一变数的深切担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBRN","SBIO","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119474444","title":"Xenon制药提交Azetukalner新药申请至FDA用于局灶性癫痫，并更新精神科临床项目进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1119474444","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119474444?lang=zh_cn&edition=full","pubTime":"2026-09-18 04:02","pubTimestamp":1789675334,"startTime":"0","endTime":"0","summary":"Xenon制药正式宣布，已就其候选药物Azetukalner向美国食品药品监督管理局提交新药申请，该药物旨在治疗局灶性癫痫。与此同时，公司还对外披露了其精神科临床项目的最新动态。此次NDA提交标志着Azetukalner在监管审批道路上迈出了关键一步。作为一款备受瞩目的在研疗法，Azetukalner的申请递交获得了业界的广泛关注，为那些饱受局灶性癫痫困扰的患者群体带来了新的希望。不仅如此，Xenon制药还借此机会，就其正在推进的精神科适应症临床开发计划提供了补充说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SBIO","IBRN","BK4139","XENE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666571008","title":"阿斯利康股价盘后跌超2%，因其三期临床试验结果令人失望。","url":"https://stock-news.laohu8.com/highlight/detail?id=2666571008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666571008?lang=zh_cn&edition=full","pubTime":"2026-09-12 04:23","pubTimestamp":1789158183,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2322448957.HKD","FTXH","MEDI","LU1992135399.USD","LU2272731865.HKD","XPH","MRNY","LFSC","PBE","IYH","IE00B5TLWC47.USD","BK4588","MRNX","LU2473716301.USD","HELX","IEHS","RXL","LU2272731600.USD","PBPH","TMED","WDNA","GNOM","FBT","BK4585","IBB","CANC","BIB","BIOY","LU2272731782.SGD","LU1992135472.HKD","PPH","BME","PSCH","BBH","RSPH","SBIO","IEIH","BBP","XBIX","IDNA","PJP","SYNB","IBRN","AZNH","LU2322448791.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664388058","title":"109亿美元重磅收购Apogee(APGE.US)落地！艾伯维(ABBV.US)完成2019年以来最大并购，预计2032年起贡献收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664388058","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664388058?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["FTXH","LU0069063385.USD","LU1551013425.SGD","FHLC","LU0124676726.USD","TRUH","LU0310800379.SGD","LU0203345920.USD","LU0170899867.USD","JDOC","IYH","VHT","SG9999003800.SGD","LU1267930490.SGD","XMMO","LU0128525929.USD","LU0320765646.SGD","RXL","LU0820561909.HKD","LU0234570918.USD","GLAM","MYLD","LU2433249047.HKD","IE0002141913.USD","LU0114720955.EUR","MEDX","LU1496350502.SGD","BK4533","IXJ","LU2237443549.SGD","IE000WAW04H5.SGD","LU0859254822.USD","LU2129689514.USD","AGNG","ABBV","LU2125909593.SGD","KCE","IE00B19Z3B42.SGD","APGE","LU2089984988.USD","LU1236620834.HKD","PPH","XLV","LU1839511570.USD","LU2237443895.HKD","PJP","LU2129689605.HKD","LU2087621335.USD","SBIO","CALF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664053388","title":"109亿美元重磅收购Apogee(APGE.US)落地！艾伯维(ABBV.US)完成2019年以来最大并购，预计2032年起贡献收益","url":"https://stock-news.laohu8.com/highlight/detail?id=2664053388","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664053388?lang=zh_cn&edition=full","pubTime":"2026-09-04 09:35","pubTimestamp":1788485746,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，艾伯维于周四表示，公司已完成对抗炎药物研发商 Apogee Therapeutics价值 109 亿美元的收购。笔交易是这家制药巨头自 2019 年以来规模最大的补强型收购，智通财经AAPP于今年 6 月首次对此进行了报道。艾伯维预计，该项收购将对其调整后稀释每股收益产生负面影响，其中 2026 年将减少 0.14 美元，2027 年减少约 0.46 美元，并预计将于 2032 年开始实现增益。该指引已包含与完成 Apogee 收购相关的每股 0.14 美元稀释效应。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1491888.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VHT","IE0004445239.USD","BK4581","IE00B19Z3581.USD","IXJ","XLV","LU0985320562.USD","MYLD","BK4566","AGNG","IE00B4R5TH58.HKD","SG9999011175.SGD","LU2237443549.SGD","LU1983299246.USD","RXL","IE00BN8TJ469.HKD","LU1236620834.HKD","APGE","LU1989772840.SGD","XMMO","FHLC","LU0057025933.USD","BK4559","LU2089283258.USD","GLAM","IE00BLSP4239.USD","ABBV","PPH","LU0256863902.USD","LU0965509283.SGD","LU1037948541.HKD","TRUH","LU0170899867.USD","PJP","LU1718418525.SGD","LU0124676726.USD","JDOC","IE0002270589.USD","LU1003077747.HKD","LU1093756168.USD","LU1934455194.USD","MEDX","LU0289739343.SGD","KCE","CALF","IYH","IE00B2B36J28.USD","LU0203345920.USD","SBIO","FTXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664521258","title":"美股异动丨诺华制药涨超7%，多发性硬化症口服药后期临床试验结果积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2664521258","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664521258?lang=zh_cn&edition=full","pubTime":"2026-09-01 22:18","pubTimestamp":1788272338,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["PSCH","PBE","IE0009355771.USD","PPH","HELX","LFSC","RXL","SYNB","BK4007","LU0211331839.USD","BBP","IEIH","MRNX","AZNH","FTXH","LU2473716301.USD","FBT","MEDX","TMED","BME","BIOY","IE00BJJMRZ35.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","PBPH","LU2272731600.USD","BK4585","IYH","SBIO","BIB","XPH","BK4588","IE0002141913.USD","LU2322448957.HKD","MEDI","RSPH","XBIX","MRNY","GNOM","IEHS","IDNA","IBB","IE00BFTCPJ56.SGD","PJP","WDNA","NVS","IE00B4R5TH58.HKD","CANC","IBRN","BBH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663282078","title":"药闻 | 英硅智能上市后首份半年报扭亏 创新药研发加速拥抱AI","url":"https://stock-news.laohu8.com/highlight/detail?id=2663282078","media":"新华财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663282078?lang=zh_cn&edition=full","pubTime":"2026-08-31 15:35","pubTimestamp":1788161758,"startTime":"0","endTime":"0","summary":"新华财经上海8月31日电（记者杜康）作为AI制药领域代表性企业之一，英硅智能（03696.HK）日前发布2026年度中期业绩报告。上半年，公司实现总营收1.063亿美元，同比增长287.2%；净利润3554万美元，经调整净利润5123万美元，经营活动现金流转正。这是英硅智能上市后发布的首份半年报，公司也由此前的亏损转为盈利。从收入结构看，药物研发与管线开发仍是主要来源。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608313860072952.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608313860072952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AGIX","GSKH","IPOS","APXH","BIOY","XLVI","AIPO","LFSC","CHAT","BBP","BK4585","VTHR","BK4588","SBIO","IBB","WRND","ARTY","QTOC","GDOC","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663044177","title":"联环药业上半年扭亏为盈 集采续采与创新药研发协同推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2663044177","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663044177?lang=zh_cn&edition=full","pubTime":"2026-08-30 21:12","pubTimestamp":1788095520,"startTime":"0","endTime":"0","summary":"业绩实现扭亏为盈经营基本面持续改善今年上半年，联环药业经营业绩实现明显改善。对此，联环药业正持续推进相关工作。值得注意的是，联环药业已经开始围绕创新药商业化进行营销体系布局。除LH-1801外，联环药业产品注册申报也取得阶段性进展。从核心产品稳定销售，到集采品种持续放量，再到创新药研发向上市申报环节推进，联环药业正在逐步形成多层次的业务增长支撑。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-30/doc-iniqcfmp8061523.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4585","GSKH","PBE","SBIO","APXH","WRND","BK0239","IBB","BIOY","LFSC","600513","BK4588","GDOC","XLVI","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659504119","title":"中国银河证券：实验动物为创新药研发刚需 小鼠+猴双主线高景气","url":"https://stock-news.laohu8.com/highlight/detail?id=2659504119","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659504119?lang=zh_cn&edition=full","pubTime":"2026-08-14 15:07","pubTimestamp":1786691225,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国银河证券发布研报称，实验动物为创新药研发刚需，行业壁垒深厚，两大细分赛道具备中长期成长逻辑：人源化小鼠赛道成长确定性更强、周期波动平缓;实验猴赛道供给约束强，短期价格上行带来显著业绩弹性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIOY","APXH","BK4585","BK1147","LFSC","BK0276","161027","BBP","WRND","BK1564","GSKH","BK0188","06881","IBB","601881","XLVI","GDOC","PBE","BK4588","SBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658903675","title":"百花医药股价严重异常波动：主营小分子化学仿制药CRO业务 不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658903675","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658903675?lang=zh_cn&edition=full","pubTime":"2026-08-12 21:27","pubTimestamp":1786541220,"startTime":"0","endTime":"0","summary":"8月12日，百花医药（维权）（600721.SH）发布公告称，公司股票连续10个交易日内日收盘价格涨幅偏离值累计超过100%，根据上交所的有关规定，属于股票交易严重异常波动情形。公司是以小分子化学仿制药研发为主的CRO企业，不涉及创新药研发。公司2026年第一季度实现营业收入6718.29万元，同比下降30.68%，归属于上市公司股东的净利润664.27万元，同比下降67.94%。目前公司主营业务未发生重大变化，市场环境、行业政策没有发生重大调整，股价短期内连续上涨，涨幅与公司经营情况严重偏离。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-12/doc-ininamih5206238.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["APXH","XLVI","BK4585","BBP","BIOY","BK0216","BK0102","GDOC","600721","IBB","PBE","WRND","SBIO","BK4588","LFSC","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658692990","title":"百花医药(600721.SH)：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658692990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658692990?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LFSC","PBE","BK4588","BBP","BK4585","IBB","WRND","APXH","SBIO","XLVI","BIOY","GDOC","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658667990","title":"百花医药(600721.SH)：不涉及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2658667990","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658667990?lang=zh_cn&edition=full","pubTime":"2026-08-11 20:03","pubTimestamp":1786449780,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百花医药(600721.SH)发布股票交易风险提示公告称，公司是以小分子化学仿制药研发为主的CRO企业，主营业务是为客户提供小分子化仿药为主的药物研发注册“一站式”全流程服务，主要研发项目多来自于客户委托加部分的公司自主立项，不涉及创新药研发。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1478640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","IBB","LFSC","GSKH","600721","BK4588","PBE","XLVI","APXH","GDOC","BK0102","SBIO","BK0216","BBP","BIOY","WRND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658604159","title":"东方证券：AI重构创新药研发底座 国内相关产业链公司亦有望受益","url":"https://stock-news.laohu8.com/highlight/detail?id=2658604159","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658604159?lang=zh_cn&edition=full","pubTime":"2026-08-11 15:29","pubTimestamp":1786433354,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，东方证券发布研报称，随着全球监管转向，AI制药规模应用正快速落地，已从早研工具演进为覆盖研发全链条的端到端体系，有望颠覆创新药研发长周期、高成本、高失败率的“反摩尔定律”。该行认为，海外MNC和科技巨头正在全面拥抱AI，而国内AI制药公司已崭露头角，相关产业链公司亦有望受益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260811/32331495.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["ARTY","GDOC","QTOC","WRND","AGIX","IBB","600958","BK0276","GSKH","BK0012","BIOY","BK4588","03958","SBIO","APXH","BK0188","VTHR","LFSC","CHAT","BK1147","XLVI","BK0028","AIPO","BK1564","BBP","BK4585","BK0183","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653584157","title":"创新药研发加速遇“猴荒”","url":"https://stock-news.laohu8.com/highlight/detail?id=2653584157","media":"三里河","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653584157?lang=zh_cn&edition=full","pubTime":"2026-07-22 16:21","pubTimestamp":1784708497,"startTime":"0","endTime":"0","summary":"“要站在‘猴’里，不要像猴子一样站在那里。”资本市场从来不缺故事。近期，昭衍新药业绩暴增，原因是实验猴市场价格上涨，带动公司手里的“猴子资产”大幅增值，多家相关概念公司股价也跟风大涨。甚至有人顺藤摸瓜，挖出了“香蕉概念”。网友戏称：这是产业链挖掘最深的一次。一只猴子，为什么能扰动资本市场？答案藏在药物的研发链条里。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607223817277458.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607223817277458.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBB","SBIO","BBP","APXH","WRND","BIOY","BK4588","XLVI","BK4585","GDOC","LFSC","GSKH","PBE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196709641","title":"ANI Pharmaceuticals 宣布拟就CG Oncology相关裁决提出上诉","url":"https://stock-news.laohu8.com/highlight/detail?id=1196709641","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196709641?lang=zh_cn&edition=full","pubTime":"2026-07-17 06:34","pubTimestamp":1784241277,"startTime":"0","endTime":"0","summary":"ANI Pharmaceuticals Inc. 宣布，计划就与CG Oncology Inc.相关诉讼中的裁决提出上诉。此前，初审法院已驳回该公司提出的重新审理及判决的动议。\n该公司表示，将继续寻求追回其在2010年出售给CG Oncology的资产价值。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","SBIO","ANIP","BK4139","LU0566484027.USD","LU1559883803.SGD","CGON"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651162210","title":"英硅智能早盘涨超7% 与康哲药业达成AI+创新药研发新合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2651162210","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651162210?lang=zh_cn&edition=full","pubTime":"2026-07-13 10:02","pubTimestamp":1783908120,"startTime":"0","endTime":"0","summary":"　　英硅智能早盘涨超7%，截至发稿，股价上涨6.21%，报45.48港元，成交额3.32亿港元。　　7月13日，据英硅智能官微消息，公司宣布与康哲药业在中枢神经系统领域开展另一项AI驱动的药物发现合作。　　根据合作协议，双方将结合英硅智能已验证的AI平台与AI赋能创新药研发能力，以及康哲药业经验丰富的研发团队和对疾病领域的深度认知，双方共同推进该研发项目的合作开发。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-13/doc-inihrnpk9058117.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["CHAT","IE00BVYPNQ40.USD","IE00BVYPNP33.GBP","GDOC","QTOC","SG9999015986.USD","IE00BYV24P56.USD","BK1593","VTHR","WRND","SG9999004220.SGD","SG9999015952.SGD","BK1191","BK4585","AIPO","SG9999015945.SGD","PBE","SBIO","00867","GSKH","IE00BMCWC346.EUR","LU2488822045.USD","AGIX","BK4588","IE00BGHQDM52.EUR","ARTY","BBP","LFSC","SG9999015978.USD","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649952006","title":"（活力中国调研行）上海生物医药产业规模破万亿 张江药谷青年人才成创新药研发主力","url":"https://stock-news.laohu8.com/highlight/detail?id=2649952006","media":"中国新闻网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649952006?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:56","pubTimestamp":1783482969,"startTime":"0","endTime":"0","summary":"中新网上海7月8日电(杨海燕马佳佳)“我们对青年人才‘如饥似渴’，上海团队有180多名全职员工，90%以上都是40岁以下的青年人才。”英硅智能全球对外合作负责人、副总裁王珏7日在“活力中国调研行”主题采访活动中介绍道。在上海张江药谷，这片曾经的农田已崛起为世界级生物医药创新高地，而活跃其中的青年人才，正成为推动创新药研发的主力军。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607083798154946.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607083798154946.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4581","BK4585","BBP","IBB","WRND","LFSC","XBI","GSKH","SBIO","GDOC","399441","PBE","161726","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649984355","title":"翰思艾泰-B(03378)：拟与华科前沿交叉研究中心打造新一代AI驱动的创新药研发范式","url":"https://stock-news.laohu8.com/highlight/detail?id=2649984355","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649984355?lang=zh_cn&edition=full","pubTime":"2026-07-07 18:57","pubTimestamp":1783421872,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰思艾泰-B 发布公告，为充分发挥产学研结合的优势，加速生物医药研发创新，公司于近日与华科—澳城大高等研究院前沿交叉研究中心正式签署了《“人工智能药物研发联合实验室”合作共建协议》。双方将依托华科前沿交叉研究中心的AI平台，以及翰思艾泰在创新药研发的丰富经验和对疾病领域的深度认知，围绕抗体发现与分子设计展开深度合作，共同打造新一代AI驱动的创新药研发范式。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464249.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LFSC","AIPO","CHAT","BK4585","BK1173","GDOC","IBB","PBE","AGIX","QTOC","03378","ARTY","GSKH","WRND","SBIO","VTHR","BBP","BK1535","BK1161","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alpsfunds.com/products/etf/SBIO","stockEarnings":[{"period":"1week","weight":-0.0012},{"period":"1month","weight":-0.0776},{"period":"3month","weight":0.1564},{"period":"6month","weight":0.3186},{"period":"1year","weight":0.7881},{"period":"ytd","weight":0.2442}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1758},{"period":"1year","weight":0.1569},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":-0.001085},{"month":2,"riseRate":0.416667,"avgChangeRate":0.006941},{"month":3,"riseRate":0.416667,"avgChangeRate":-0.031697},{"month":4,"riseRate":0.5,"avgChangeRate":0.010069},{"month":5,"riseRate":0.583333,"avgChangeRate":0.022132},{"month":6,"riseRate":0.666667,"avgChangeRate":0.043666},{"month":7,"riseRate":0.666667,"avgChangeRate":0.025453},{"month":8,"riseRate":0.583333,"avgChangeRate":0.011469},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.01911},{"month":10,"riseRate":0.636364,"avgChangeRate":0.000571},{"month":11,"riseRate":0.818182,"avgChangeRate":0.058537},{"month":12,"riseRate":0.454545,"avgChangeRate":0.000399}],"exchange":"ARCA","name":"ALPS Medical Breakthroughs ETF","nameEN":"ALPS Medical Breakthroughs ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ALPS Medical Breakthroughs ETF(SBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供ALPS Medical Breakthroughs ETF(SBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"ALPS Medical Breakthroughs ETF,SBIO,ALPS Medical Breakthroughs ETF股票,ALPS Medical Breakthroughs ETF股票老虎,ALPS Medical Breakthroughs ETF股票老虎国际,ALPS Medical Breakthroughs ETF行情,ALPS Medical Breakthroughs ETF股票行情,ALPS Medical Breakthroughs ETF股价,ALPS Medical Breakthroughs ETF股市,ALPS Medical Breakthroughs ETF股票价格,ALPS Medical Breakthroughs ETF股票交易,ALPS Medical Breakthroughs ETF股票购买,ALPS Medical Breakthroughs ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ALPS Medical Breakthroughs ETF(SBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供ALPS Medical Breakthroughs ETF(SBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}